← All trials
NCT00742248
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2004
- Primary completion
- May 1, 2005
- Completion date
- May 1, 2005
- First posted
- —
- Last posted
- —
- Enrollment
- 54
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- ChiesiLead sponsor
- University of GenoaOverall official - principal investigator
- University of PisaOverall official - principal investigator
- University of GenoaStudy director
- University of Modena and Reggio EmiliaCollaborator
- University of PisaCollaborator
- Azienda Ospedaliera Antonio CardarelliCollaborator
- Fondazione Don Carlo Gnocchi OnlusCollaborator
- S. Corona HospitalCollaborator
- University of GenoaCollaborator
- Azienda Ospedaliera Antonio CardarelliOverall official - principal investigator
- S. Corona HospitalOverall official - principal investigator
- University of Modena and Reggio EmiliaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.